Tezspire

TEZSPIRE Eosinophilic Esophagitis Trial: Amgen, AstraZeneca Report Positive Phase 3 CROSSING Results

By Clinical Trials & Data Desk
27 August 2026

Amgen and AstraZeneca announced that TEZSPIRE (tezepelumab-ekko) achieved statistically significant and clinically meaningful results across both co-primary endpoints and all key secondary endpoints in the Phase 3 CROSSING trial in eosinophilic esophagitis, with benefits sustained through week 52.

Regulatory Approval News

AstraZeneca’s Tezspire Gains EU Approval for Nasal Polyps, Offering New Hope for Patients

By Ajmal Aseem
22 October 2025

The European Commission has officially approved AstraZeneca’s Tezspire (tezepelumab) for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP). This new add-on therapy offers hope for patients whose condition is uncontrolled by standard treatments, demonstrating efficacy in reducing polyp size, alleviating congestion, and decreasing the need for surgery.

Tag: Tezspire

TEZSPIRE Eosinophilic Esophagitis Trial: Amgen, AstraZeneca Report Positive Phase 3 CROSSING Results

AstraZeneca’s Tezspire Gains EU Approval for Nasal Polyps, Offering New Hope for Patients

Areas Covered

Discover More

AstraZeneca’s Enhertu EU Approval: Enhertu Plus Pertuzumab Cleared as First-Line Therapy for HER2-Positive Metastatic Breast Cancer

Lilly Merida Biosciences Acquisition: Eli Lilly to Pay $2.875 Billion for Precision Autoantibody Therapies

Roche Vabysmo PCV Study Shows Sustained Two-Year Results in Difficult-to-Treat nAMD Subtype

TEZSPIRE Eosinophilic Esophagitis Trial: Amgen, AstraZeneca Report Positive Phase 3 CROSSING Results

Abbott Libre Duo 10 Day Wins FDA Authorization as World’s First Dual Glucose-Ketone Sensor

Johnson & Johnson’s IMAAVY Nipocalimab-aahu Wins FDA Approval as First-Ever Treatment for Warm Autoimmune Hemolytic Anemia